All In Biotech

Drug Trial Radar · NCT00421993

A Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris

A Multi-Center, Randomized, Double-Blind, Parallel-Group Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel Compared With Adapalene Topical Gel, 0.1%; Benzoyl Peroxide Topical Gel, 2.5% and Topical Gel Vehicle in Subjects With Acne Vulgaris

Last checked: Nov 19, 2026Latest source record: Feb 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,670 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,670

Actual

Start

Oct 2006

Primary completion

Oct 2007

Study completion Dec 2007

Sponsor

Lead sponsor
Galderma R&DIndustry
Sponsor type
Industry
First posted
Jan 15, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, randomized, double-blind, parallel group study with 12 weeks of treatment of acne vulgaris. Efficacy and safety evaluations will be performed at Screening (safety only), Baseline and Weeks 1, 2, 4, 8 and 12. All Investigator's Global Assessment evaluators and lesion counters must be trained and approved by Galderma. The evaluator of a subject should remain the same during the study. The primary objective is to demonstrate the superiority in efficacy and assess safety of Adapalene/Benzoyl Peroxide Topical Gel (Adapalene/Benzoyl Peroxide Gel) versus Adapalene Topical Gel, 0.1% (Adapalene Monad); Benzoyl Peroxide Topical Gel, 2.5% (Benzoyl Peroxide Monad) and Topical Gel Vehicle (Gel Vehicle) in the treatment of acne vulgaris for up to 12 weeks.

Conditions

  • Acne Vulgaris

Interventions

  • Adapalene/Benzoyl PeroxideDrug

    Topical Gel, One application daily in the evening for 12 weeks

  • AdapaleneDrug

    Topical Gel,One application daily in the evening for 12 weeks

  • Benzoyl PeroxideDrug

    Topical Gel, one application daily in the evening for 12 weeks

  • Topical Gel VehicleDrug

    Topical Gel Vehicle,one application daily in the evening for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Success Rate on the Investigator's Global AssessmentTime frame: at week 12
  2. Changes in Inflammatory Lesion CountsTime frame: from Baseline to week 12
  3. Changes in Noninflammatory Lesion CountsTime frame: from Baseline to week 12

Locations

62 sites in 5 countries. Site status is shown where the registry gives one.

  • Medical Affliated Research Center

    Huntsville, Alabama

  • Dermatology Research of Arkansas

    Little Rock, Arkansas

  • Associates in research, Inc.

    Fresno, California

  • University of California, Irvine

    Irvine, California

  • Dermatology Research Associates

    Los Angeles, California

  • Marcia J. Glenn, MD and Associates, Dermatology & Laser center, Inc

    Marina del Rey, California

  • Affiliated Research Institute

    San Diego, California

  • University at San Francisco Medical Center

    San Francisco, California

  • Radiant Research

    Santa Rosa, California

  • Dr Weintraub James

    Simi Valley, California

  • The George Washington University Medical Center

    Washington D.C., District of Columbia

  • Visions Clinical Research

    West Palm Beach, Florida

  • Atlanta Dermatology and Vein Research Center

    Alpharetta, Georgia

  • SKINQRI

    Lincolnshire, Illinois

  • Welborn Clinic

    Evansville, Indiana

  • Dawes Fretzin Clinical Research Group, LLC

    Indianapolis, Indiana

  • Dolby Research, LLC

    Baton Rouge, Louisiana

  • Hamzavi Dermatology

    Port Huron, Michigan

  • Somerset Skin Clinic

    Troy, Michigan

  • James Del Rosso, DO - Office of Dr. James Del Russo

    Henderson, Nevada

  • Dartmouth-Hitchcock Medical Center

    Lebanon, New Hampshire

  • Skin Specialty Group

    New York, New York

  • Derm Research Center of NY, Inc.

    Stony Brook, New York

  • Zoe Draelos

    High Point, North Carolina

  • OU Health Sciences Center - Dept. of Dermatology

    Oklahoma City, Oklahoma

  • Allergy, Asthma and Dermatology Research Center, LLC

    Lake Oswego, Oregon

  • Radiant Research

    Anderson, South Carolina

  • Dermatology Associates of Knoxville

    Knoxville, Tennessee

  • Arlington Center for Dermatology

    Arlington, Texas

  • UTSW Medical Center at Dallas

    Dallas, Texas

  • University of Texas Medical Branch at Galveston

    Galveston, Texas

  • Tanner Clinic

    Layton, Utah

  • Fletcher Allen Health Care

    Burlington, Vermont

  • The Dermatology Centre

    Calgary, Alberta, Canada

  • Stratica Medical

    Edmonton, Alberta, Canada

  • Guildford Dermatology Specialists

    Surrey, British Columbia, Canada

  • Derm Research @ 888 Inc.

    Vancouver, British Columbia, Canada

  • Winnipeg Clinic

    Winnipeg, Manitoba, Canada

  • Dermadvances Research

    Winnipeg, Manitoba, Canada

  • Nexus clinical research

    St. John's, Newfoundland and Labrador, Canada

Showing 40 of 62 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.